Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

Long-term data from Opdivo plus Yervoy-based combinations demonstrate durable survival in metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, including results from landmark five-year analysis of CheckMate -227 in NSCLC

First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm

New data from pivotal MEDALIST and BELIEVE studies of Reblozyl in myelodysplastic syndromes and beta thalassemia highlight long-term anemia control in serious myeloid diseases

Data from pivotal RELATIVITY -047 trial studying Opdualag reinforce efficacy of LAG-3 mechanism in advanced melanoma

Excerpt from the Press Release:

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress that underscores the company’s commitment to delivering transformational therapies for patients. Data from more than 140 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds across 28 cancer types and blood disorders will be featured at the two meetings.

“We have made significant progress for patients with cancer and blood disorders by delivering clinically meaningful and differentiated treatment choices across modalities such as CAR T, immunotherapy and erythroid maturation,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “Driven by our deep understanding of human biology and leading scientific research, the results being presented at ASCO and EHA will provide greater insight into the potential for improving long-term outcomes, and rationale for moving innovative interventions into earlier lines of treatment. Beyond our data, we are focused on improving care for all patients through our Health Equity Commitments, aimed at increasing diversity in clinical trials, addressing health disparities, and investing in training for racially and ethnically diverse clinical investigators.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release